Cyclosporin A induces in vivo inhibition of resorption and stimulation of formation in rat bone.
We investigated a possible "in vivo" effect of cyclosporin A, an immunosuppressive agent, on normal rat bone remodeling. At an oral daily dose of 7 mg/kg for 14 days, the blood level of cyclosporin A was in the usual effective range and no change in renal function or magnesium metabolism was observed. Treated rats had decreased bone resorption: urinary hydroxyproline, plasma acid phosphatase, and the number of osteoclasts in caudal vertebrae were significantly reduced. By contrast, bone formation assessed by dynamic histomorphometry after double tetracycline labeling was increased. No modification of calciotropic hormones (vitamin D metabolites and parathyroid hormone as assessed by urinary cyclic AMP) was observed at the end of the treatment. These results suggest that in vivo cyclosporin A treatment induces bone remodeling modifications related to either a direct or a lymphokine-mediated effect on bone cells.
INSERM U 18, Hôpital Lariboisière, Paris, France.
P
P
Orcel
J
J
Bielakoff
D
D
Modrowski
L
L
Miravet
M C
MC
de Vernejoul
D000135:Acid Phosphatase / Q000097:blood; D000818:Animals; D001846:Bone Development / Q000187:drug effects*; D001862:Bone Resorption / Q000187:drug effects*; D002452:Cell Count; D003524:Cyclosporins / Q000494:pharmacology*; D005260:Female; D006909:Hydroxyproline / Q000652:urine; D010010:Osteoclasts / Q000187:drug effects; D051381:Rats; D011919:Rats, Inbred Strains
D003524:Cyclosporins; D000135:Acid Phosphatase; D006909:Hydroxyproline